European Association of Nuclear Medicine

Last updated
European Association of Nuclear Medicine
AbbreviationEANM
FormationSeptember 6, 1985;38 years ago (1985-09-06)
TypeNon-profit organisation, scientific society
Headquarters Vienna, Austria
Official language
English
Website eanm.org

The European Association of Nuclear Medicine (EANM) is the leading professional organisation for nuclear medicine in Europe. Established in 1985, the EANM serves as an umbrella organisation comprising national societies, affiliated societies and individual members working in nuclear medicine or related fields. It is also dedicated to the promotion of nuclear medicine amongst other medical learned societies, EU institutions like the European Union, international organisations like the International Atomic Energy Agency, and the general public. [1]

Contents

The EANM also obtained international recognition for its annual congress, which gathers about 7,500 participants, [2] and for its ESMIT teaching programme, launched in 2015 in Vienna, Austria. Additionally, the EANM has its own monthly peer-reviewed medical journal, the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI). [3]

History

The EANM was founded in 1985 in London, United Kingdom following the union of the Society of Nuclear Medicine Europe and the European Nuclear Medicine Society. [4]

The first EANM Congress took place in 1988 in Milan, Italy. [5] Since then, the EANM Annual Conference has been taking place in multiples countries, including Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Portugal, Scotland, Spain, Sweden, Switzerland, The Netherlands, Turkey, and the United Kingdom. [6]

The EANM's headquarters are based in Vienna, Austria. The EANM is also represented in Brussels, Belgium, where the organisation closely works with the European Commission and partner organisations. [7]

Structure

The EANM is governed by an elected Board of international experts in nuclear medicine. The Board serves as the top executive body of the organisation. The elected Presidents, who serve a two-year mandate and represent the organisation, are supported by their team to expand the EANM’s outreach. [8]

Nuclear medicine being used in many medical disciplines, the EANM’s volunteers are divided into Committees and Councils, which focus on promoting nuclear medicine in different areas, including: [9]

The Executive Office, based in Vienna, oversees all the logistical aspects, ranging from organising scientific events, to managing publications and establishing new partnerships, and promoting the organisation among EU institutions and international organisations. The Executive Office also organises the Annual Congress and managed the ESMIT courses. [10]

Membership-wise, the EANM currently comprises 40 national societies, 20 non-European affiliated societies and 2,900 individual members from 80 countries from Europe and beyond. The EANM is also supported by a team of over 150 volunteers, who work within the Board and the Committees. [11]

Activities

Annual Congress

EANM'16 in Barcelona, Spain Eanm-congress-2016 30423435055 o.jpg
EANM'16 in Barcelona, Spain

The EANM Annual Congress features scientific sessions, workshops, and interactive discussions led by speakers. [12] It brings together international experts and professionals in the field of nuclear medicine to discuss the latest advancements and innovations in nuclear medicine and molecular imaging. [13]

EU Affairs

The EANM closely works with EU institutions and EU policymakers to shed more light on the properties of nuclear medicine and to ensure that EU citizens have access to high-quality and safe therapeutic nuclear medicine. [14]

For instance, as part of the European Commission’s SAMIRA Action Plan, the EANM is part of the consortium performing the SIMPLERAD Project, which seeks to ensure that Euratom radiation protection requirements and the EU legislation concerning the therapeutic use of radiopharmaceuticals are implemented. [15]

Publications


The EANM’s official journal is the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI).

The EJNMMI serves as a platform for the dissemination of research and advancements in the field of nuclear medicine and molecular imaging. It publishes original articles, reviews, case reports, and guidelines that cover various aspects of nuclear medicine, radiopharmaceuticals, imaging techniques, and their clinical applications. [16]

ESMIT

ESMIT's official logo ESMIT.jpg
ESMIT's official logo

The EANM is highly active in the field of education. Its European School of Multimodality Imaging & Therapy (ESMIT) was founded in 2015 as a response to the rising demand for educational programmes focusing on nuclear medicine. [17]

The EANM launched ESMIT to equip health professionals with knowledge about both the modalities of nuclear medicine and its therapeutic applications. With the help of experienced faculty members, the EANM thus offers a wide range of learning experiences, ranging from in-person advanced courses, to live webinars and an eLearning platform. [18]

EARL

The EANM established EANM Forschungs GmbH, also known as EANM Research Ltd. (EARL), in 2006 to promote standardised quantification in nuclear medicine imaging. [19] As a subsidiary of the EANM, EARL's primary goal is to enhance nuclear medicine practice, drive scientific initiatives, and facilitate clinical research projects. [20]

Related Research Articles

Radionuclide therapy uses radioactive substances called radiopharmaceuticals to treat medical conditions, particularly cancer. These are introduced into the body by various means and localise to specific locations, organs or tissues depending on their properties and administration routes. This includes anything from a simple compound such as sodium iodide that locates to the thyroid via trapping the iodide ion, to complex biopharmaceuticals such as recombinant antibodies which are attached to radionuclides and seek out specific antigens on cell surfaces.

<span class="mw-page-title-main">Bone scintigraphy</span> Nuclear medicine imaging technique

A bone scan or bone scintigraphy is a nuclear medicine imaging technique of the bone. It can help diagnose a number of bone conditions, including cancer of the bone or metastasis, location of bone inflammation and fractures, and bone infection (osteomyelitis).

<span class="mw-page-title-main">Ibritumomab tiuxetan</span> Radioimmunotherapy treatment

Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.

<span class="mw-page-title-main">Radioisotope renography</span>

Radioisotope renography is a form of medical imaging of the kidneys that uses radiolabelling. A renogram, which may also be known as a MAG3 scan, allows a nuclear medicine physician or a radiologist to visualize the kidneys and learn more about how they are functioning. MAG3 is an acronym for mercapto acetyl tri glycine, a compound that is chelated with a radioactive element – technetium-99m.

A gallium scan is a type of nuclear medicine test that uses either a gallium-67 (67Ga) or gallium-68 (68Ga) radiopharmaceutical to obtain images of a specific type of tissue, or disease state of tissue. Gallium salts like gallium citrate and gallium nitrate may be used. The form of salt is not important, since it is the freely dissolved gallium ion Ga3+ which is active. Both 67Ga and 68Ga salts have similar uptake mechanisms. Gallium can also be used in other forms, for example 68Ga-PSMA is used for cancer imaging. The gamma emission of gallium-67 is imaged by a gamma camera, while the positron emission of gallium-68 is imaged by positron emission tomography (PET).

<span class="mw-page-title-main">Nuclear pharmacy</span> Branch of pharmacy focused on radioactive pharmaceuticals

Nuclear pharmacy, also known as radiopharmacy, involves preparation of radioactive materials for patient administration that will be used to diagnose and treat specific diseases in nuclear medicine. It generally involves the practice of combining a radionuclide tracer with a pharmaceutical component that determines the biological localization in the patient. Radiopharmaceuticals are generally not designed to have a therapeutic effect themselves, but there is a risk to staff from radiation exposure and to patients from possible contamination in production. Due to these intersecting risks, nuclear pharmacy is a heavily regulated field. The majority of diagnostic nuclear medicine investigations are performed using technetium-99m.

<span class="mw-page-title-main">18F-EF5</span> Chemical compound

EF5 is a nitroimidazole derivative used in oncology research. Due to its similarity in chemical structure to etanidazole, EF5 binds in cells displaying hypoxia.

Technetium 99mTc albumin aggregated (99mTc-MAA) is an injectable radiopharmaceutical used in nuclear medicine. It consists of a sterile aqueous suspension of Technetium-99m (99mTc) labeled to human albumin aggregate particles. It is commonly used for lung perfusion scanning. It is also less commonly used to visualise a peritoneovenous shunt and for isotope venography.

Ioflupane (<sup>123</sup>I) Chemical compound

Ioflupane (123I) is the international nonproprietary name (INN) of a cocaine analogue which is a neuro-imaging radiopharmaceutical drug, used in nuclear medicine for the diagnosis of Parkinson's disease and the differential diagnosis of Parkinson's disease over other disorders presenting similar symptoms. During the DaT scan procedure it is injected into a patient and viewed with a gamma camera in order to acquire SPECT images of the brain with particular respect to the striatum, a subcortical region of the basal ganglia. The drug is sold under the brand name Datscan and is manufactured by GE Healthcare, formerly Amersham plc.

<span class="mw-page-title-main">Iobenguane</span> Chemical compound

Iobenguane, or MIBG, is an aralkylguanidine analog of the adrenergic neurotransmitter norepinephrine (noradrenaline), typically used as a radiopharmaceutical. It acts as a blocking agent for adrenergic neurons. When radiolabeled, it can be used in nuclear medicinal diagnostic and therapy techniques as well as in neuroendocrine chemotherapy treatments.

The American Board of Nuclear Medicine (ABNM) certifies physicians as specialists in the practice of nuclear medicine. Diplomates of the ABNM are called nuclear medicine physicians. The ABNM is one of the 24 member boards of the American Board of Medical Specialties (ABMS).

Nuclear medicine physicians, also called nuclear radiologists or simply nucleologists, are medical specialists that use tracers, usually radiopharmaceuticals, for diagnosis and therapy. Nuclear medicine procedures are the major clinical applications of molecular imaging and molecular therapy. In the United States, nuclear medicine physicians are certified by the American Board of Nuclear Medicine and the American Osteopathic Board of Nuclear Medicine.

<i>European Journal of Nuclear Medicine and Molecular Imaging</i> Peer-reviewed medical journal

The European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) is a peer-reviewed medical journal published by Springer. It is the official journal of the European Association of Nuclear Medicine. Since 1976, the EJNMMI has published material related to the field of nuclear medicine, including dosimetry, radiation biology, radiochemistry, radiopharmacology, molecular imaging probes, reporter gene assays, cell trafficking, targeting of endogenous gene expression, and antisense methodologies. As of 2021, the EJNMMI has an impact factor of 10.057.

<span class="mw-page-title-main">DOTA-TATE</span> Eight amino-acid long peptide covalently bonded to a DOTA chelator

DOTA-TATE is an eight amino acid long peptide, with a covalently bonded DOTA bifunctional chelator.

Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.

A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 (68Ga), copper-64 (64Cu), and fluorine-18 (18F) is carried out with a positron emission tomography (PET) scanner. For gamma emitters such as technetium-99m (99mTc) and indium-111 (111In) single-photon emission computed tomography (SPECT) imaging is performed with a gamma camera.

<span class="mw-page-title-main">Peptide receptor radionuclide therapy</span> Type of radiotherapy

Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs).

Lutetium (<sup>177</sup>Lu) oxodotreotide Chelate of Lu-177 with dotatate, a peptide derivative bound to a DOTA molecule

Lutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. It is a radiolabeled somatostatin analog.

Angelika Bischof-Delaloye is a former emeritus professor at the University of Lausanne in Lausanne, Switzerland.

Gallium (<sup>68</sup>Ga) gozetotide Radiopharmaceutical medication

Gallium (68Ga) gozetotide or Gallium (68Ga) PSMA-11 sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68Ga conjugated to prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx)-HBED-CC, used for imaging prostate cancer by positron emission tomography (PET). The PSMA targeting ligand specifically directs the radiolabeled imaging agent towards the prostate cancerous lesions in men.

References

  1. ↑ "IAEA Director General at EANM Annual Congress: Nuclear Medicine is Key for Global Health". International Atomic Energy Agency. International Atomic Energy Agency News. 23 October 2017. Retrieved May 26, 2023.
  2. ↑ EANM. "Statistics EANM'23 Vienna" (PDF). eanm.org. Retrieved December 12, 2023.
  3. ↑ "What is the European Journal of Nuclear Medicine and Molecular Imaging?". May 26, 2023. Retrieved May 26, 2023.
  4. ↑ Ell, Peter J. (November 1996). "Nuclear Medicine Organizations in Europe" (PDF). The Journal of Nuclear Medicine. 37 (11): 26–31. PMID   8917166 . Retrieved May 26, 2023.
  5. ↑ "European Nuclear Medicine Congress 1985. London, 3-6 September 1985. Abstracts". Nuc Med Commun. 535 (9): 611. 1985. PMID   3877893 . Retrieved May 26, 2023.
  6. ↑ "EANM Past Congresses". EANM. 8 November 2016. Retrieved May 26, 2023.
  7. ↑ De Rimini, Maria Luisa. "European Association of Nuclear Medicine - EANM" (PDF). Seguici Events. UOC Medicina Nucleare, AORN Ospedali dei Colli, Napoli. Retrieved May 26, 2023.
  8. ↑ "Erba prepares to become president elect of EANM". AuntMinnieEurope.com. Retrieved May 26, 2023.
  9. ↑ M. Lassmann & L. Biassoni & M. Monsieurs & C. Franzius & F. Jacobs & (4 April 2007). "The new EANM paediatric dosage card" (PDF). Eur J Nucl Med Mol Imaging. 34 (1): 796–798. doi:10.1007/s00259-007-0370-0. PMID   17406866. S2CID   32939710.
  10. ↑ "EANM Executive Office". EANM. 31 October 2016. Retrieved May 26, 2023.
  11. ↑ "General Information". European Association of Nuclear Medicine. Retrieved June 26, 2023.
  12. ↑ "Diagnostics and therapy in prostate cancer were hot topics at EANM meeting". Rad Magazine. November 11, 2019. Retrieved May 26, 2023.
  13. ↑ Matassa, Giovanni; Gelardi, Fabrizia; Hustinx, Roland; Chiti, Arturo (April 28, 2021). "Highlights of 33rd EANM Annual Congress 2020, virtual edition". European Journal of Nuclear Medicine and Molecular Imaging. 48 (8): 2314–2318. doi:10.1007/s00259-021-05366-4. PMC   8079516 . PMID   33909087.
  14. ↑ "Research 4 Life". Simplerad. Retrieved May 31, 2023.
  15. ↑ "SAMIRA Action Plan". European Commission.
  16. ↑ "About". European Journal of Nuclear Medicine and Molecular Imaging. Retrieved May 31, 2023.
  17. ↑ "New Initiative: The European School of Multimodality Imaging and Therapy". SSNM. Retrieved May 26, 2023.
  18. ↑ "ESMIT Online Education". EANM. 3 November 2016. Retrieved May 26, 2023.
  19. ↑ "Welcome". Research 4 Life. Retrieved May 26, 2023.
  20. ↑ Andres Kaalep, Terez Sera, Wim Oyen, Bernd J. Krause, Arturo Chiti, Yan Liu, and Ronald Boellaard (2018). "EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems". Eur J Nucl Med Mol Imaging. 45 (3): 412–422. doi:10.1007/s00259-017-3853-7. PMC   5787222 . PMID   29192365.{{cite journal}}: CS1 maint: multiple names: authors list (link)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.